Moesin modulators and uses thereof

a moesin and modulator technology, applied in the field of moesin modulator and moesin activity, can solve the problems of unreliable correlation between clinical manifestation and anti-erm antibodies, and achieve the effect of effectively treating or preventing mammal

Inactive Publication Date: 2015-09-03
SHANGHAI KEXIN BIOTECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0023]In one aspect, the present application provides a method of therapeutically treating a mammal having a cancerous tumor comprising a cell with abnormal activation of moesin, said method comprising administering to said mammal an effective amount of a modulator molecule of the present application, thereby effectively treating said mammal.
[0024]In one aspect, the present application provides a method for treating or preventing a cell proliferative disorder associated with abnormal activation of moesin, said method comprising administering to a subject in need of such treatment an effective amount of an a modulator molecule of the present application, thereby effectively treating or preventing said cell proliferative disorder. In one embodiment, said proliferative disorder is cancer. In yet another embodiment, said proliferative disorder is organ fibrosis such as pulmonary fibrosis, cystic fibrosis, cirrhosis, endomyocardial fibrosis, myelofibrosis, retroperitoneal fibrosis, Crohn's Disease, Keloid, systemic sclerosis or progressive massive fibrosis.

Problems solved by technology

However, the study did not find significant correlation between the presence of anti-ERM antibodies and clinical manifestation, such as disease duration or stage.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Moesin modulators and uses thereof
  • Moesin modulators and uses thereof
  • Moesin modulators and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of the Anti-moesin Antibodies

[0129]Monoclonal antibody against the C-terminal tail domain of moesin was prepared by using the conventional hybridoma methods. To generate the C-terminal domain having the sequence of SEQ ID NO:1, PCR was used to amplify cDNA fragments corresponding to the C-terminal tail domain as described above (see SEQ ID NO:4 shown in FIG. 1B, wherein the underlined portion is the cDNA sequence of the C-terminal tail domain).

[0130]PCR-amplified moesin DNA fragments were cloned into expression vectors selected from pET32a(+) and pET28a(+). The constructed vectors were then used to transform E. coli host cell line BL21(DE3) for culturing and expression. The restriction and cloning maps of pET32a(+) and pET28a(+) are shown in FIGS. 2A and 2B, respectively. The constructed expression systems for the C-terminal domain were verified with restriction enzyme digestion followed by sequencing to confirm the correct reading frame for expression of the C-terminal ...

example 2

Assessing Moesin Inhibitor's Ability to Inhibit Cell Proliferations

[0135]This experiment is used to assess moesin inhibitor's ability to inhibit or reduce cell proliferation.

[0136]Cell proliferation assay were performed using a human pulmonary microvascular endothelial cell line (HPMEC). Cells were plated in each well on a 6-well plate at 106 cells / cm2, and cultured at room temperature in the presence of various testing and control reagents as described below. After culturing for a determined period of time, cells were collected and labeled for flow cytometry analysis. Proliferation rates at 2 hrs, 24 hrs and 36 hrs were determined by dividing the mean OD570 value from the tested groups with the mean OD570 value from the group having the same number of cells as the test groups at the beginning of the cell culturing.

[0137]Tested and control groups are as follows:[0138]1) TNF-alpha alone;[0139]2) Antibody against full length moesin protein (anti-Moesin);[0140]3) Antibody against the C...

example 3

Analysis of Intercellular Expression of Moesin and Apoptosis

[0145]Cell cultures in the presence of anti-moesin antibodies as described in Example 1 were subjected to apoptosis assay as well as surface antigen assay, to assess the antibody's effect on promoting endothelial cell apoptosis and on intercellular expression of moesin (indicating the active form of the protein).

[0146]Annexin V assay was used to study apoptosis. Collected cells were washed with PBS, centrifuged, and added sequentially with 70% ethanol, RNAs (200 mg / 1) and PI (20 mg / 1). Cells were then stained with Annexin-V FITC / PI kit for double staining of FITC and PI, because viable cells are both FITC and PI negative, while cells that are in early apoptosis are FITC positive but PI negative, and cells that are in late apoptosis or already dead are both FITC and PI positive. Stained cells are analyzed using a flow cytometer for amount of apoptotic cells in the presence of variant testing agents. The percentage of cells i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
compositionaaaaaaaaaa
cell-surface structuresaaaaaaaaaa
Login to view more

Abstract

The present application provides compositions and methods useful for treating and diagnosing diseases and disorders associated with moesin activation.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. Non-Provisional application Ser. No. 13 / 878,232 filed on Apr. 8, 2013, which is a National Stage Application of International Application Number PCT / CN2011 / 080520 filed on Oct. 8, 2011, which claims the priority of International Application Number PCT / CN2010 / 077589 filed on Oct. 8, 2010, all of which are incorporated by reference herein in their entirety.TECHNICAL FIELD[0002]The present application relates generally to the field of molecular biology and medicine. More specifically, the present application concerns methods and compositions for modulating moesin activities and related conditions.BACKGROUND[0003]Moesin, which stands for membrane-organizing extension spike protein, is a membrane bound intracellular protein initially indentified in bovine uterus and characterized as a possible receptor for heparin. Lankes et al., Biochem J. 251:831-42 (1988). Full length native human moesin has 577 amin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K45/06A61K38/10C07K7/08A61K38/08C07K16/18C07K7/06
CPCA61K39/3955C07K16/18A61K45/06C07K2317/76C07K7/08A61K38/08A61K38/10C07K7/06A61K38/191A61K38/2006A61K38/204A61K38/2086A61P1/00A61P1/04A61P9/00A61P9/02A61P11/00A61P17/00A61P17/02A61P19/00A61P35/00A61P37/00A61P37/08A61P43/00C07K16/28C07K2317/73A61K2300/00A61K38/16A61K39/395
Inventor ZHANG, YUEBAO, JUNMAO, HUASHOU, ZHINANSITU, WEINA
Owner SHANGHAI KEXIN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap